SARS-CoV-2 resistance pathways to EDP-235.
Wang K, Gibbons JS, Bisht N, Reyes AC, Cressey TN, Crepeau ML, Balakrishnan A, Kelly NM, Bai T, Lovett DH, Torres Yanagisawa AE, Caccin FNM, Rhodin MHJ, Iketani S
Antiviral Res. 2026 Sep;253:106493. doi: 10.1016/j.antiviral.2026.106493. Epub 2026 Jul 27.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 254472 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-P132S-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with P132S mutation fused to nsp4 and an N-terminal fragment of nsp6. |
| 254473 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-P168S-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with P168S mutation fused to nsp4 and an N-terminal fragment of nsp6. |
| 254474 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-L50F-E166A-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with L50F and E166A mutations fused to nsp4 and an N-terminal fragment of nsp6. |
| 254475 | pLEX307-puro-SARS-CoV-2-nsp4-nsp5-L50F-E166A-P168S-nsp6 | Constitutive expression of SARS-CoV-2 nsp5 with L50F, E166A, and P168S mutations fused to nsp4 and an N-terminal fragment of nsp6. |